On September 5, 2025, the National Administration of Medicines, Food, and Medical Technology (ANMAT) issued Provision No. 6559/2025, expanding the requirement of bioequivalence and/or bioavailability studies to oral pharmaceutical forms of hypoglycemic drugs.
This measure applies to medicinal products whose…
By Moeller IP Advisors
In Peru, patent coverage for branded pharmaceuticals lasts for 20 years from the date of filing, in line with most jurisdictions. Once the 20-year term has expired, the same product can be marketed as generic. A…
